LOVE THIS PART!!!
In other news, the Company will commence Scientific Advice discussions with the European Medicines Agency (EMA) this week, via a scheduled meeting, to review plans for the international Phase 3 Brilacidin Oral Mucositis program. Also in the coming weeks, the Company plans to provide an update on its Brilacidin program for the treatment of Inflammatory Bowel Disease.
IPIX